{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-086101","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.068814+00:00","generated_at":"2026-06-08T05:55:01.389992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell Q3 product sales up 13% to $5.4M but gross margin halved on contamination events; net loss widens","bullets":["Product sales $5.4M (+13% YoY) for Q3 2023; nine-month sales $12.4M (-16% YoY).","Gross margin fell to 23% (Q3 2023) from 38% (Q3 2022) due to production contamination and inventory write-offs.","Net loss $940k ($0.12/share) vs $655k ($0.08/share) in Q3 2022; nine-month loss $4.6M ($0.60) vs $826k ($0.11).","Cash decreased to $2.0M from $5.8M at Dec 2022; no draw on $1M credit line.","Finished goods produced rose sequentially from $3.3M to $4M to $5.3M across Q1-Q3; goal is $6M/quarter (80% of capacity)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-086101","json":"https://secwatch.observer/filing/0001213900-23-086101.json","markdown":"https://secwatch.observer/filing/0001213900-23-086101.md","text":"https://secwatch.observer/filing/0001213900-23-086101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390023086101/0001213900-23-086101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390023086101/ea188130-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:55:01.389992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54f5979269c8e33d3d0bd77301e45a68c33078e9","claim":"IMMUCELL CORP /DE/ reported the quarter ended September 30, 2023 results: revenue $5.4 million, net income Net loss was $940,000, or $0.12 per basic share, EPS $0.12 per basic share.","evidence_excerpt":"to traditional antibiotics that is subject to FDA approval,” concluded Mr. Brigham. 1 of 6 Certain Financial Results: ● Product sales increased by 13%, or $600,000, to $5.4 million during the three-month period ended September 30, 2023 compared to $4.8 million during the three-month period ended September 30, 2022. ● Product sales decreased by 16%, or $2.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023086101/0001213900-23-086101-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.4 million"},{"label":"Net income","value":"Net loss was $940,000, or $0.12 per basic share"},{"label":"EPS","value":"$0.12 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}